138 related articles for article (PubMed ID: 38294552)
1. Comment on "Risk of gastric cancer among long‑term proton pump inhibitor users: a population‑based cohort study".
Lai SW; Hwang BF; Liu CS; Liao KF
Eur J Clin Pharmacol; 2024 Apr; 80(4):621-622. PubMed ID: 38294552
[No Abstract] [Full Text] [Related]
2. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
3. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
5. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.
Song TJ; Kim J
PLoS One; 2019; 14(5):e0216750. PubMed ID: 31067267
[TBL] [Abstract][Full Text] [Related]
6. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.
Liu P; McMenamin ÚC; Johnston BT; Murchie P; Iversen L; Lee AJ; Vissers PAJ; Cardwell CR
Br J Cancer; 2020 Jul; 123(2):307-315. PubMed ID: 32367073
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitor Use Associated With an Increased Risk of Gastric Cancer.
Am Fam Physician; 2022 Jul; 106(1):99C. PubMed ID: 35839349
[No Abstract] [Full Text] [Related]
8. Proton pump inhibitors and risk of gastric cancer: population-based cohort study.
Abrahami D; McDonald EG; Schnitzer ME; Barkun AN; Suissa S; Azoulay L
Gut; 2022 Jan; 71(1):16-24. PubMed ID: 34226290
[TBL] [Abstract][Full Text] [Related]
9. Gastric Acid Suppressant Prophylaxis in Pediatric Intensive Care: Current Practice as Reflected in a Large Administrative Database.
Costarino AT; Dai D; Feng R; Feudtner C; Guevara JP
Pediatr Crit Care Med; 2015 Sep; 16(7):605-12. PubMed ID: 25901549
[TBL] [Abstract][Full Text] [Related]
10. Optimal duration of proton pump inhibitor for healing artificial ulcers after endoscopic submucosal dissection for early gastric cancer.
Gotoda T
Dig Dis Sci; 2012 Feb; 57(2):266-8. PubMed ID: 22198705
[No Abstract] [Full Text] [Related]
11. What is the optimum prophylaxis against gastrointestinal haemorrhage for patients undergoing adult cardiac surgery: histamine receptor antagonists, or proton-pump inhibitors?
Patel AJ; Som R
Interact Cardiovasc Thorac Surg; 2013 Mar; 16(3):356-60. PubMed ID: 23208652
[TBL] [Abstract][Full Text] [Related]
12. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies.
Ahn JS; Eom CS; Jeon CY; Park SM
World J Gastroenterol; 2013 Apr; 19(16):2560-8. PubMed ID: 23674860
[TBL] [Abstract][Full Text] [Related]
13. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Haga Y; Nakatsura T; Shibata Y; Sameshima H; Nakamura Y; Tanimura M; Ogawa M
Dig Dis Sci; 1998 Feb; 43(2):253-7. PubMed ID: 9512115
[No Abstract] [Full Text] [Related]
14. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
Brusselaers N; Sadr-Azodi O; Engstrand L
J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
[TBL] [Abstract][Full Text] [Related]
15. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
[TBL] [Abstract][Full Text] [Related]
16. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
17. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
Xue S; Katz PO; Banerjee P; Tutuian R; Castell DO
Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
19. Use of proton pump inhibitors for the risk of gastric cancer.
Gao H; Li L; Geng K; Teng C; Chen Y; Chu F; Zhao Y
Medicine (Baltimore); 2022 Dec; 101(49):e32228. PubMed ID: 36626449
[TBL] [Abstract][Full Text] [Related]
20. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
